Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and ...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

Philadelphia Works Names First Female Chief Operating Officer • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • Statement from the Chief Public Health Officer of Canada on World TB Day • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • Build community with shared future, create better world • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga • Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • National University Receives 2023 Military Friendly® Gold Designation • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges

Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

WILMINGTON, Mass. , February 09 /Businesswire/ - Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22^nd, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 22^nd, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.